Finasteride
| 證據等級: L5 | 預測適應症: 6 個 |
目錄
Using the drug-repurposing evaluation report format supplied in the system prompt to structure this response.
Note on methodology before the report: The evidence pack’s own repurposing_rationale fields flag ranks 1, 3, 4, 5, 6 (Ambras hypertrichosis, periodontal malformation, Dandy-Walker syndrome, hair shaft abnormality, trichomegaly) as likely TxGNN knowledge-graph embedding artifacts — no mechanistic link to finasteride’s DHT pathway and zero supporting trials/literature (evidence level L5, Hold). Rank 2 (“hypertrichosis (disease)”) is the only candidate with a coherent mechanism and actual literature/trial hits. As the report should not headline noise, this report is built around rank 2 rather than the raw top-ranked (but non-credible) prediction.
Finasteride: From Androgenetic Alopecia to Hypertrichosis
One-Sentence Summary
Finasteride is a 5α-reductase inhibitor used to treat androgen-dependent hair loss (androgenetic alopecia). Of the six TxGNN-predicted indications in this evidence pack, only Hypertrichosis (rank 2, score 99.99%) has a biologically coherent mechanism and any supporting evidence base — 1 clinical trial and 4 publications — though none directly test finasteride in this indication. The other five top-ranked predictions were screened out as likely false-positive knowledge-graph associations.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Androgenetic alopecia (male pattern hair loss) — not confirmed via South Africa regulatory filings (see below) |
| Predicted New Indication | Hypertrichosis (disease) |
| TxGNN Prediction Score | 99.99% |
| Evidence Level | L4 |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data is not available in this evidence pack (original_moa: [Data Gap]). Based on well-established pharmacology referenced within the pack’s own literature (e.g. PMID 12942187), finasteride is a 5α-reductase inhibitor that blocks conversion of testosterone to dihydrotestosterone (DHT). It is used clinically for androgen-dependent hair conditions — reducing DHT-driven follicular miniaturisation in androgenetic alopecia.
Hypertrichosis and androgenetic alopecia sit at opposite ends of the same hair-growth axis, and the mechanistic case is only partial: per the evidence pack’s own literature (PMID 12223963), most adult hypertrichosis is not androgen-dependent — it is iatrogenic (minoxidil, ciclosporine, diazoxide, glucocorticoids), metabolic (porphyria), nutritional, or paraneoplastic. A DHT-lowering drug would plausibly help only the androgen-dependent subset (i.e., hirsutism-type presentations), not hypertrichosis broadly. This is why the evidence level is capped at L4 (mechanism-only) rather than higher.
The other five TxGNN top predictions in this pack (Ambras syndrome, periodontal malformation syndrome, Dandy-Walker malformation, isolated hair shaft abnormality, familial trichomegaly) were reviewed and excluded from this report: each is annotated in the source data as having no plausible mechanistic link to DHT/5α-reductase biology, no supporting trials, and no supporting literature — consistent with knowledge-graph node-proximity noise rather than a genuine repurposing signal.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT04293822 | Phase 4 | Unknown | 60 | Compares topical cetirizine gel vs. minoxidil 5% gel for androgenetic alopecia (AGA). Note: does not investigate finasteride and does not study hypertrichosis — flagged in the source data as relevance grade C (low relevance), included only via disease-node proximity. |
No SANCTR or PACTR-registered trials were identified in this evidence pack.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 12942187 | 2003 | Review | Der Hautarzt | Notes finasteride’s established use in male pattern hair loss alongside laser hair removal for hypertrichosis/hirsutism — the strongest textual link between finasteride and this indication class, but does not report direct finasteride trial data for hypertrichosis. |
| 12223963 | 2002 | Review | Annales de Dermatologie et de Vénéréologie | Distinguishes hypertrichosis (non-androgen-dependent) from hirsutism (androgen-dependent); indicates hormonal-mechanism drugs are relevant mainly to the hirsutism subset. |
| 10330884 | 1999 | Review | Therapeutische Umschau | General review of treatment options for androgenetic alopecia and hirsutism, including oral therapy for male pattern hair loss. |
| 12444520 | 2002 | Review | Der Hautarzt | Describes TrichoScan, a digital hair-analysis tool for monitoring hair-loss treatment response; methodological reference, not disease-specific evidence. |
South Africa Market Information
Finasteride currently has no SAHPRA registrations in this evidence pack (market_status: 未上市 / Not marketed, total_licenses: 0). No product listings, dosage forms, or approved indication text are available to summarise.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
(Note: this evidence pack flags PI warnings/contraindications as a Blocking data gap (DG001) — this must be resolved before any safety assessment can proceed.)
Conclusion and Next Steps
Decision: Hold
Rationale:
- No direct clinical or literature evidence tests finasteride in hypertrichosis or hirsutism specifically — the single trial identified doesn’t use finasteride, and all four literature hits are indirect/contextual reviews (evidence level L4, mechanism-only).
- Finasteride is not currently marketed in South Africa (0 SAHPRA registrations), and PI-based safety data is a documented Blocking gap (DG001), so a formal safety review (S1) cannot be completed yet.
To proceed, the following is needed:
- SAHPRA/TFDA-approved Professional Information (warnings, contraindications) to close the Blocking safety gap
- Confirmed original indication and mechanism-of-action documentation (currently marked Data Gap)
- A direct interventional study of finasteride specifically in androgen-dependent hypertrichosis or hirsutism, rather than androgenetic alopecia alone
- Assessment of regulatory pathway/route feasibility if pursuing South African market entry for this drug
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.